# Evaluation of Varenicline (Champix) in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA) Trial

> **NCT00794573** · PHASE3 · COMPLETED · sponsor: **Mark Eisenberg** · enrollment: 302 (actual)

## Conditions studied

- Acute Coronary Syndrome

## Interventions

- **DRUG:** varenicline
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00794573
- **Lead sponsor:** Mark Eisenberg
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2015-06
- **Final completion:** 2015-12
- **Target enrollment:** 302 (ACTUAL)
- **Last updated:** 2019-05-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00794573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00794573, "Evaluation of Varenicline (Champix) in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA) Trial". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT00794573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*